CardioKinetix Obtains $44,000,000 Series E Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d8ea8f74-ed68-497d-9ea2-13b57b2499a4&Preview=1 - Date
9/21/2011 - Company Name
CardioKinetix - Mailing Address
925 Hamilton Avenue Menlo Park, CA 94025 - Company Description
CardioKinetix, Inc. is developing new technology for treating Congestive Heart Failure (CHF). This is a catheter-based intervention implanted into the heart. CHF results from damage to the heart from several causes, which affects nearly five million people in the U.S. - Website
http://www.cardiokinetix.com - Transaction Type
Venture Equity - Transaction Amount
$44,000,000 - Transaction Round
Series E - Proceeds Purposes
This financing provides CardioKinetix the capital necessary to substantially progress the development of our PARACHUTE™ device, including conducting clinical studies to further support the initial commercialization of Parachute in Europe and a PMA submission to FDA. - M&A Terms
- Venture Investor
SV Life Sciences - Venture Investor
New Leaf Venture Partners - Venture Investor
U.S. Venture Partners - Venture Investor
JPMorgan Partners - Venture Investor
Undisclosed
